Innoviva Specialty Therapeutics, a subsidiary of Innoviva Inc., today announced that its infectious disease therapeutic portfolio earned a strong performance rating of 80% in the 2026 Antimicrobial ...

Introduction Glucose is a major determinant of fetal growth, but its relative contribution in different ethnic groups or populations is not fully understood. The Hyperglycaemia and Adverse Pregnancy ...

These expectant mothers were wracked by morning sickness, until two cheap remedies changed everything... overnight!

TONMYA (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults, was commercially launched in November 2025Treatment ...

Treatment with TONMYA provided statistically significant pain reduction in two Phase 3 trials and was generally well tolerated BERKELEY HEIGHTS, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Tonix ...

KOMZIFTI™ (ziftomenib) launch generating early revenue momentum and rapid payer coverage decisions – – Market feedback emphasizes differentiated safety, combinability and convenience of ziftomenib, su ...

Commercially launched in the U.S. in November 2025, TONMYA (cyclobenzaprine HCl sublingual tablets) for long-term daily dosing at bedtime is the first new FDA-approved treatment for fibromyalgia in ...

Introduction Gastroschisis mortality is disproportionately high in Africa due in part to delayed presentation and limited ...

Approval based on unprecedented Phase 3 data demonstrating statistically significant improvements in progression-free survival and overall survival versus standard of care regimens83.3% of ...

Desperate wannabe parents are betting their life savings on unproven treatments and false promises ...